checkAd
    Startseite > Aktien > Cullinan Oncology > Nachrichten
    Cullinan Oncology Aktie
    23,810
     
    USD
    -10,89 %
    -2,910 USD
    Letzter Kurs 23:20:00 Nasdaq
    23,740
     
    USD
    100 STK
    Geldkurs 22:02:00
    23,810
     
    USD
    300 STK
    Briefkurs 22:02:00
    ISIN: US2300311063 · WKN: A2QL3C · SYM: CGEM · USA

    Neueste Nachrichten

    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
    15.05.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
    29.04.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
    24.04.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
    16.04.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
    16.04.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    14.03.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
    01.03.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology to Participate in Upcoming Investor Conferences
    27.02.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    18.12.23 · globenewswire · Cullinan Oncology
    Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
    14.12.23 · globenewswire · Cullinan Oncology
    Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
    08.11.23 · globenewswire · Cullinan Oncology
    Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
    03.11.23 · globenewswire · Cullinan Oncology